Immunic AGErik Lundgren assumed his role as the new CEO of Immunic. He succeeds Dr Daniel Vitt, who will continue to oversee the biotech company’s scientific strategy.
SantheraMarc Clausse will take up his new role as Chief Commercial Officer at Santhera Pharmaceuticals (SIX: SANN) at the beginning of June. He succeeds Geert Jan van Daal, who is retiring.
AC Immune SADr Andrea Pfeifer, long-serving CEO and co-founder from AC Immune, has decided to retire. AC Immune’s Board of Directors has appointed the Chair, Dr Martin Zügel, to serve as interim CEO while the ongoing search for a permanent successor continues.
Resyca BVDr Deborah Jones joined the Dutch Resyca BV as CEO at the beginning of April, succeeding Remko Beimers, who has stepped down from his role.
AnaveonSwiss biotech company Anaveon has appointed a new Chief Executive Officer. As the company announced in March, experienced biopharma executive Thaminda Ramanayake will take over the leadership of the Basel-based firm.
NovartisIn March, Mukul Mehta took over as the new Chief Financial Officer at Basel-based Biotech and Pharma Company Novartis. At the same time, he became a member of the Executive Committee.
eXmoor PharmaBristol-based cell and gene therapy CDMO eXmoor Pharma appointed Manuel Balbuena as Chief Commercial Officer at the beginning of March.
SymeresJurgen Berendsen has returned to Symeres (Nijmegen, NL) as Chief Financial Officer. His appointment took place at the beginning of this year.
Qureight LtdCambridge-based techbio company Qureight Ltd has appointed Rebecca Simmons as its new Chief Operating Officer in January.
WLan HoldingFairJourney Biologics (Porto, PT) has appointed Dr Werner Lanthaler, long-standing Evotec CEO, as Chief Executive Officer. Founder António Parada will focus on innovation strategy on the Supervisory Board.